Ziopharm Oncology Inc. (ZIOP) gained in early trading after reporting positive results from a study on an experimental treatment for brain cancer. The biotech company said its

Ziopharm Oncology Inc. (ZIOP) gained in early trading after reporting positive results from a study on an experimental treatment for brain cancer. The biotech company said its Ad-RTS-IL-12 gene therapy showed potent anti-tumor and anti-cancer stem cell effects on a model of brain cancer. Human and laboratory studies of Ad-RTS-IL-12 showed that precise control of IL-12, a protein for stimulating an immune response against cancer, can be achieved using Intrexon Corp.’s (XON) RheoSwitch Therapeutic System. The findings were presented at the annual meeting of the American Society of Gene and Cell Therapy in Washington. Ziopharm jumped 8.7% to $3.39 a share in early trading on Friday. It has traded from $1.80 to $5.58 in the past 52 weeks. Intrexon closed at $17.84 a share on Thursday. It has traded from a 52-week high of $38.50 on January 21 to a low of $13.13 on May 9.